Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/195
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ryan, Jennifer | en |
dc.contributor.author | Warrier, Satish | en |
dc.contributor.author | Lynch, A. Craig | en |
dc.contributor.author | Heriot, Alexander | en |
dc.date.accessioned | 2015-06-09T00:25:48Z | en |
dc.date.available | 2015-06-09T00:25:48Z | en |
dc.date.issued | 2014-07 | en |
dc.identifier.uri | http://hdl.handle.net/11434/195 | en |
dc.description.abstract | Aim: Pathological complete response (pCR) of rectal cancer to neoadjuvant chemoradiotherapy (nCRT) confers a survival advantage and the potential to avoid surgery in selected cases. The aim was to assess the role of 18 FGD PET CT in the identification of pCR. Method: Patients with advanced rectal cancer (including 26 patients with stage IV disease) undergoing nCRT and surgery at a tertiary centre were identified from a prospective database. All patients underwent 18 FDG PET CT scans prior to and after nCRT and metabolic response [complete (CMR), partial (PMR)] was assessed. Complete pathological response (pCR) was assessed on the resected specimen. Results: Pathological complete response was identified in 34 out of 195 patients (138M, 57F) Cancer specific survival was 86.7% with a local recurrence (LR) rate of 6.15%. 64 (32.8%) patients had a CMR on PET. The accuracy, sensitivity, and specificity of PET CT to predict pCR was: 70%, 59%, and 73% respectively. Both pCR and CMR identified patient groups with superior prognosis. 5 years survival was 97% for pCR, and 87.5% in CMR. No patient with pCR had a LR compared with 1.5%in MCR and 8.2% for those with a PMR. All 20 patients with both a pCR and CMR had 100% cancer specific survival. Conclusion: FDG PET CT has moderate accuracy in identification of pCR, however CMR identifies patients with low risk of local recurrence and 100% cancer specific survival when combined with pCR. | en |
dc.subject | Chemoradiotherapy, Adjuvant | en |
dc.subject | Rectal Cancer | en |
dc.subject | Positron-Emission Tomography | en |
dc.subject | X-Ray Micro-CT Scans | en |
dc.subject | 18FDG | en |
dc.subject | Fluorodeoxyglucose F18 | en |
dc.subject | Rectal Neoplasms | en |
dc.subject | Cancer of the Rectum | en |
dc.subject | Rectal Cancer | en |
dc.subject | Rectal Tumors | en |
dc.subject | Tumors or Cancer of the Rectum | en |
dc.subject | Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia | - |
dc.title | Does 18 FDG PET CT predict complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer? | en |
dc.type | Conference Paper | en |
dc.description.affiliates | Division of Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia | en |
dc.description.affiliates | Department of Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia | en |
dc.type.studyortrial | Reviews/Systematic Reviews | en |
dc.description.conferencename | Tripartite Colorectal Meeting of the American Society of Colon and Rectal Surgeons, ASCRS; Association of Coloproctology of GB and Ireland; the Section of Coloproctology, Royal Society of Medicine; the Colon and Rectal Surgery Section. | en |
dc.description.conferencelocation | Birmingham, United Kingdom | en |
dc.type.contenttype | Text | en |
Appears in Collections: | Cancer Services |
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.